Name: Marlen All-Flexible Compact Convex Mounting Ring,7/8 Opening,Each,GN-102C
Brand: MARLEN MANUFACTURING & DEVELOPMENT CO.
SKU: 33091-173474
Price: 35.99 USD
Availability: InStock

Marlen All-Flexible Compact Convex Mounting Ring,7/8 Opening,Each,GN-102C - 33091-173474

By MARLEN MANUFACTURING & DEVELOPMENT CO.

$35.99

(629 Reviews)

Model

33091-173474

Store

Health Products For You

Manufacturer

MARLEN MANUFACTURING & DEVELOPMENT CO.

Detail

Marlen All-Flexible Compact Convex Mounting Ring is for persons with fleshier abdomens and short or flush stomas. The 1/4 (6mm) convexity applies slight pressure to the stomal area, allowing the stoma to stay within the mounting ring opening and not retract. It is for the smaller person with a well-positioned stoma.

Category

Ostomy

SAN FRANCISCO -- Awake prone positioning did not reduce endotracheal intubation at 30 days compared with usual care in patients with acute hypoxemic respiratory failure from COVID-19, according to results of the COVI-PRONE trial. At 30 days, 34.1% of patients randomly assigned to awake prone positioning were intubated compared with 40.5% of patients assigned usual care without prone positioning (HR = 0.81; 95% CI, 0.59-1.12; P = .2), Waleed Alhazzani, MD, MSc, associate professor in the department of medicine at McMaster University in Hamilton, Ontario, Canada, said during a presentation ...

>Read More

SAN FRANCISCO -- Treatment with an oral preferential phosphodiesterase 4B inhibitor prevented lung function decline among patients with idiopathic pulmonary fibrosis, regardless of background antifibrotic therapy use. The phase 2 trial enrolled 147 adults with IPF who were randomly assigned to an oral preferential inhibitor of the phosphodiesterase 4B (PDE4B) subtype (BI 1015550, Boehringer Ingelheim) at a dose of 18 mg or placebo twice daily. Treatment continued for 12 weeks, followed by a 1-week follow-up period. Treatment with the PDE4B inhibitor appeared to stabilize lung function ...

>Read More

SAN FRANCISCO -- In patients with uncontrolled moderate to severe asthma, a fixed-dose combination of albuterol and budesonide used as an as-needed rescue medication lowered risk for severe asthma exacerbations compared with albuterol alone. MANDALA met its primary endpoint: Albuterol-budesonide significantly reduced exacerbation risk vs. albuterol, Alberto Papi, MD, professor of respiratory medicine at University of Ferrara Medical School in Italy, said during a presentation of the findings at the American Thoracic Society International Conference. Results were ...

>Read More

DESTIN, Fla. -- Hydroxychloroquine may no longer be the optimal treatment option for systemic dermatomyositis, according to data presented at the Congress of Clinical Rheumatology East. In her presentation, Avery H. LaChance, MD, MPH, director of the Connective Tissue Diseases Clinic at Brigham and Womens Hospital, and assistant professor of dermatology at Harvard Medical School, said she has moved on from hydroxychloroquine as a first-line systemic therapy for systemic dermatomyositis. The only time I am reaching for hydroxychloroquine is in patients with super mild disease, ...

>Read More

FORT LAUDERDALE, Fla. -- Avoiding retinal breaks is important when treating tabletop traction retinal detachment cases, according to a speaker here. You have to do everything you can to not make iatrogenic retinal breaks. You have to still have scissors in your wheelhouse. You have to learn how to use scissors and maintain that skillset for these tabletop traction retinal detachment cases, Steve Charles, MD, said at the Retina World Congress. If you try to do it all with the cutter, youre going to make retinal breaks. Beveled tip cutters, smaller cutter ...

>Read More

DESTIN, Fla. -- Early treatment can provide patients with axial spondyloarthritis a better opportunity to achieve drug-free remission and slow disease progression, according to a speaker at the Congress of Clinical Rheumatology East 2022. Specifically, Janus kinase inhibitors such as tofacitinib (Xeljanz, Pfizer), upadacitinib (Rinvoq, AbbVie) and filgotinib (Gilead Sciences/ Galapagos NV) have demonstrated capacity to reduce spine and sacroiliac joint inflammation as measured by MRIs, said Nigel Haroon, MD, PhD, DM, MBA, FRCPC, head of the rheumatology department at the University Health ...

>Read More

Product Details for 33091-173474